PDRN and exosomes are not interchangeable. PDRN is a defined molecule — fragmented DNA that acts largely through the adenosine A2A receptor — with genuine placebo-controlled human evidence in wound healing, though far less in aesthetics. Exosomes are cell-derived vesicles carrying mixed biological cargo, with no FDA-approved products and a human evidence base that is almost entirely uncontrolled. The regulatory gap between them is the real story.
Clinics market these two as sibling “regenerative boosters,” priced within shouting distance of each other, often on the same menu. That framing is convenient and wrong. They differ in what they are, how consistent they are batch to batch, what the trials actually measured, and — most importantly for anyone in the United States — what legal footing the treatment stands on.
This page compares them honestly, which means saying where PDRN’s own evidence is thinner than its marketing, not just where exosome marketing outruns its data.
What is PDRN and how does it actually work?
PDRN (polydeoxyribonucleotide) is a mixture of DNA fragments, typically extracted from salmon or salmon trout sperm. Galeano and colleagues describe the sourcing as Oncorhynchus mykiss or Oncorhynchus keta, purified to greater than 95% active principle without pharmacologically active proteins and peptides. That last clause matters: the purification deliberately strips out protein signalling molecules. What is left is nucleic acid.
It works through two documented routes:
- Adenosine A2A receptor activation. PDRN behaves as an A2A agonist. Receptor binding raises intracellular cAMP, which reduces inflammatory cytokine output and promotes angiogenesis and fibroblast activity. Galeano’s group notes A2A receptors are expressed on most cell types involved in wound healing, and that blocking the receptor with an antagonist abolished the benefit in experimental models — which is the kind of experiment that makes a mechanism credible rather than merely plausible.
- The salvage pathway. The fragments are broken down into nucleotides and nucleosides that cells reuse to build new DNA, rather than synthesising it from scratch. Colangelo and colleagues frame PDRN as “a prodrug that provides active deoxyribonucleotides for purinergic receptor binding.”
The practical consequence: PDRN is a chemically definable substance with a known receptor target. You can characterise a batch. You can antagonise its mechanism to prove causation. Our breakdown of the cellular mechanism behind PDRN’s healing effect goes deeper on the signalling cascade.
One naming caveat worth carrying into any consultation. Kim’s 2025 comparison in Pharmaceutics notes that PN (polynucleotide) chains are longer and more viscous, working substantially through hydrogel-like hydration and structural support, while PDRN relies more on A2A signalling and the salvage pathway. Kim also warns that “the same active compounds may be classified differently across countries,” with no standardised molecular weight thresholds separating the two. Rejuran, the product most people mean when they say “PDRN injection,” is technically a PN product. Clinics use the terms interchangeably. The literature does not.
What are exosomes and how do they differ mechanistically?
Exosomes are extracellular vesicles — membrane-bound packets released by cells, carrying a cargo of miRNA, proteins, growth factors and lipids. They are a delivery vehicle, not a molecule. The therapeutic claim is that the cargo reprograms recipient cells: modulating inflammation, upregulating collagen and elastin, suppressing matrix metalloproteinases.
The difference from PDRN cuts in an underappreciated direction. PDRN’s mechanism is narrow and specific — one main receptor, one salvage route. Exosome cargo depends on the source cell, the culture conditions, and the isolation method. That breadth is marketed as an advantage. It is also why the category struggles with standardisation.
The Alzahrani 2026 systematic review in Dermatology Practical & Conceptual puts it plainly: “The lack of standardized EV characterization and quantification protocols hinders reproducibility and clinical translation.” Two vials labelled “exosomes” from two suppliers are not necessarily the same product in any meaningful sense.
| PDRN | Exosomes | |
|---|---|---|
| What it is | Defined DNA fragment mixture | Cell-derived vesicles, heterogeneous cargo |
| Typical source | Salmon / salmon trout sperm | Cultured stem cells, other cell lines |
| Primary mechanism | Adenosine A2A receptor agonism + salvage pathway | miRNA / protein cargo transfer to recipient cells |
| Mechanism proven by antagonism? | Yes — A2A blockade abolishes effect | No equivalent single-target test |
| Batch standardisation | Characterisable; MW thresholds still unstandardised | No standardised characterisation protocols |
| Strongest human evidence | Diabetic foot ulcer healing (placebo-controlled RCT) | Pooled uncontrolled/open-label aesthetic studies |
| US regulatory status (aesthetic) | Not FDA-approved for aesthetic injection | No FDA-approved products; regulated as drugs/biologics |
What does the human evidence actually support for PDRN?
PDRN’s best evidence is not cosmetic. It is a wound.
Squadrito and colleagues ran a randomised, double-blind, placebo-controlled trial across two Italian centres in patients with hard-to-heal diabetic foot ulcers (Wagner grade 1 or 2). 106 received placebo, 110 received PDRN, over 8 weeks. Complete healing reached 37.3% in the PDRN group versus 18.9% on placebo (P = .0027). Median time to closure fell from 49 days to 30. That is a real trial with a hard endpoint and a clinically meaningful result, registered on ClinicalTrials.gov as NCT00638872 — a Phase 4 study with 215 actual participants, listed as completed. (No results are posted to the registry itself; the findings live in the journal publication.)
Now the part clinic pages omit.
The flagship aesthetic PDRN trial — Pak and colleagues’ 2014 phase III, randomised, double-blind, matched-pairs study of Rejuran versus hyaluronic acid filler for crow’s feet in the Journal of Korean Medical Science — was retracted in 2016. The retraction notice is published in the same journal at 31(2):330.
Even taking the original paper at face value before retraction, read its own results: “the primary and secondary objective efficacy outcome measure showed no statistical significance between the two groups.” The headline aesthetic study for the best-known PDRN product reported a null primary endpoint against an active comparator, then was withdrawn from the record.
That does not mean PDRN does nothing for skin. It means the specific claim “PDRN outperforms filler for wrinkles, proven in a phase III trial” has no standing. Colangelo’s review concludes that “bigger RCTs with robust endpoints are needed.” That was 2020, and it remains the honest position. Our complete review of the PDRN clinical evidence and our look at the data behind PDRN’s marketing claims work through the rest of the trial base.
What does the human evidence actually support for exosomes?
More studies than you would expect, weaker designs than you would hope.
Stack and colleagues’ 2026 systematic review and meta-analysis in Aesthetic Surgery Journal pooled 39 human studies — 26 on skin, 13 on hair. Facial wrinkle reduction averaged 20.2% (95% CI, 15.3%–25.2%; P < .001). Other skin outcomes improved 14.7% to 23.4%; hair density improved 23.6%.
Those numbers look persuasive until you read the limitations the authors themselves flag. “Many studies were limited by small sample sizes, lacked control groups or were nonrandomized.” Follow-up was typically 6–12 weeks. Exosome origin, formulation, delivery method and outcome measures varied across studies. And the line that should govern how much weight you give the pooled figure: risk of bias assessment “was often not feasible because of the predominance of open-label or single-arm designs.”
A 20.2% pooled improvement drawn largely from uncontrolled, unblinded, short-follow-up studies is a hypothesis, not a demonstrated effect size. Skin measured 8 weeks after any procedure — with attentive aftercare, sun avoidance, and a patient who wants it to have worked — improves for reasons that have nothing to do with the vial.
The Alzahrani review is starker. Of 21 included studies, roughly 9 were human, and only one was a randomised controlled trial: a 12-week split-face study of 28 participants using adipose stem cell exosomes with microneedling.
So the state of play: PDRN has one strong RCT in a non-aesthetic indication and a retracted null trial in its main aesthetic one. Exosomes have volume without control groups. We cover the shared biology in more depth in our piece on PDRN and exosomes as the next frontier in skin aging.
Are exosome treatments FDA-approved? The regulatory reality
This is where the two genuinely part company, and it is the question most comparison pages will not answer straight.
There are no FDA-approved exosome products. The FDA said so in its Public Safety Notification on Exosome Products, issued December 6, 2019, and the agency has not resiled from it. The notification is worth quoting directly, because it anticipates the exact sales pitch patients hear:
They may claim that these products do not fall under the regulatory provisions for drugs and biological products — that is simply untrue. As a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food Drug and Cosmetic Act and are subject to premarket review and approval requirements.
The notification was prompted by serious adverse events in Nebraska patients treated with unapproved exosome products, reported to FDA via the CDC. The CDC’s own guidance states flatly: “The FDA has not approved any exosome products for any uses.”
This is not stale 2019 history. FDA’s Center for Biologics Evaluation and Research is still issuing warning letters. In December 2024 it wrote to Evolutionary Biologics Inc. regarding an exosome product, stating the products “are unapproved new drugs and are also unlicensed biological products.” In September 2025 it wrote to New Life Medical Services, LLC about an exosome product, again citing violations of section 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act. Enforcement is live and ongoing.
Now the part that is fair to PDRN’s critics. PDRN is not FDA-approved for aesthetic injection in the United States either, and its overseas approvals are routinely overstated.
Kim’s 2025 review sets out what those approvals actually are. In South Korea, PDRN products such as Placentex, Newdien Injection and PDRN Injection are regulated as pharmaceutical agents — but the approved indication is “the treatment of graft-induced wounds and tissue regeneration,” not wrinkles. Rejuran, meanwhile, is classified in Korea as a medical device, not a drug. Placentex is a PDRN therapeutic developed by Mastelli S.R.L. in Italy using a proprietary purification technology. Kim also notes PDRN appears in topical cosmetics registered simply as sodium DNA or hydrolyzed DNA.
Read that carefully, because it undercuts the most common consultation-room line. “Rejuran is approved in Korea” is true only in the sense that a medical device is approved. It is not a drug approval, and it is not an approval for the cosmetic outcome being sold. None of it is US approval for cosmetic use.
The distinction between the two treatments is real but narrower than PDRN marketing implies:
- Exosomes: an entire product class with zero approved products anywhere in the US, an active FDA safety notification naming the category, and documented enforcement against sellers as recently as September 2025.
- PDRN: an approved drug substance in other jurisdictions with a defined pharmacological identity — but approved there for wounds and tissue regeneration, not aesthetics, and not approved by FDA for aesthetic indications at all.
Neither is a treatment your insurance covers or that FDA has vouched for cosmetically. One is unapproved-in-this-country-and-off-indication-everywhere. The other is unapproved-anywhere-and-under-enforcement. If a US clinic tells you either treatment is “FDA-approved,” ask them to put it in writing. Our global PDRN regulatory status overview maps the jurisdiction-by-jurisdiction picture.
Which is safer?
On documented harm, PDRN has the better record — largely because it has been a registered drug somewhere for three decades and its safety data accumulated alongside that.
The Squadrito trial reported no safety signal that stopped the study. Even the retracted Pak trial noted “no unexpected adverse effects.” PDRN’s typical reported issues are procedural rather than pharmacological: injection-site swelling, bruising, tenderness, small papules. Our fact-versus-fiction breakdown of PDRN side effects covers this ground.
For exosomes, the concerning data is regulatory rather than trial-derived. The FDA’s 2019 notification exists because patients were seriously harmed, and the CDC documented bacterial infections following unapproved products in this category. The harm in the Nebraska cases traced to contamination and absent manufacturing control — not the exosome concept failing, but no approved pathway meaning nobody independently verified what was in the vial.
That is the honest safety framing: exosomes are not demonstrably dangerous as a biological idea. They are risky as a purchase, because product identity is unverifiable and manufacturing is unpoliced.
What about cost?
Both are out-of-pocket. Neither is insurance-reimbursed in the US, because neither is an approved aesthetic indication — so pricing is set entirely by individual clinics rather than by any published or negotiated schedule.
We are not going to invent national average figures; no authoritative pricing source exists for either treatment, and the numbers circulating on clinic pages are marketing, not data. Structurally: both are typically sold as courses rather than single sessions, and exosome treatments generally sit at the premium end of clinic menus. Ask for the full course price, not the per-session price, and ask what happens if you stop halfway. Our PDRN treatment cost breakdown covers the PDRN side in more detail.
Who should consider which?
PDRN may make more sense if you want a defined substance with a characterised mechanism and a real regulatory identity somewhere, you are targeting skin quality rather than volume, and you accept that its aesthetic evidence is far weaker than its wound-healing evidence.
Exosomes may appeal if you are comfortable being early to a technology whose human aesthetic data is real in volume but poor in design — and, in the US, you understand you are buying a product the FDA has publicly warned about and is actively pursuing.
Neither is right if you have been told one is proven to outperform the other. No head-to-head trial of PDRN against exosomes exists that we could locate. Anyone claiming a winner is extrapolating.
For a comparison with a deeper trial base on both sides, PDRN versus PRP is a more evidentially settled question. We also maintain a shorter side-by-side at our PDRN vs exosomes comparison page.
Frequently asked questions
Can PDRN and exosomes be combined in one session? Clinics offer it. We found no human trial testing the combination for safety or added benefit, so any claim that stacking them is synergistic is currently untested speculation. Discuss it with a qualified provider rather than assuming additive effects.
Is the FDA warning about exosomes only for IV or systemic use? No. The 2019 notification addresses exosome products used to treat diseases and conditions in humans as a category, stating such products are regulated as drugs and biological products subject to premarket review. It is not limited to a single route of administration.
Does “topical exosome serum” carry the same regulatory issue as injected exosomes? FDA’s stated concern attaches to products intended to treat disease or affect the structure or function of the body — the language quoted in its warning letters. Where a topical sits depends on the claims made for it. We could not verify a clean, general FDA statement covering cosmetic-claim topical exosome products specifically, so we are not going to assert one.
Is PDRN’s salmon origin an allergy concern for fish-allergic patients? Galeano’s review describes purification to over 95% active principle explicitly without pharmacologically active proteins and peptides, and protein is what drives fish allergy. That is a reassuring purification target rather than a guarantee for any individual — a question for a clinician who knows your allergy history.
Why do clinics present these as equivalent? Both fit the “regenerative booster” slot on a menu, both are injected or microneedled, and both appeal to patients who want skin quality rather than volume. Commercial similarity is not biological similarity.
The honest summary
PDRN has a credible, receptor-level mechanism and one genuinely good placebo-controlled trial — in diabetic foot ulcers. Its marquee aesthetic trial was retracted, and reported a null primary endpoint before it was. Exosomes have an appealing mechanistic story, a large but methodologically weak human literature, no FDA-approved products, an active federal safety notification, and enforcement letters as recent as September 2025.
Neither category has earned the certainty in which it is sold. PDRN is the more conservative choice on regulatory and manufacturing grounds — a statement about risk and product integrity, not a claim that it works better for your face. The trial that was supposed to show that does not exist any more.
Take this to a qualified provider, ask what evidence they are relying on, and ask them to name the study.